Abstract
Chemical genetics, genomics, and proteomics have been in existence as distinct offshoots of chemical biology for about 20 years. This review provides a brief definition of each, followed by some examples of how each technology is being used to advance basic research and drug discovery.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Leathes JB (1930) The Harveian oration on the birth of chemical biology. Br Med J 2:671–676
MacBeath G (2001) Chemical genomics: what will it take and who gets to play? Genome Biol doi:10.1186/gb-2001-2-6-comment 2005
Schreiber SL (1998) Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg Med Chem 6:1127–52
Jessani N, Liu Y, Humphrey M, Cravatt BF (2002) Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci USA 99:10335–40
Jeffery DA, Bogyo M (2003) Chemical proteomics and its application to drug discovery. Curr Opin Biotechnol 14:87–95
Chen TF et al. (2000) A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR) Proc Natl Acad Sci USA 97:13227–32
Caron P (2005) Introduction to Chemical Genomics. In: Zanders ED (ed) Chemical Genomics, Reviews and Protocols. Humana Press, New Jersey
Stockwell BR (2000) Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 1:116–25
Rix U, Superti-Furga G (2009) Target profiling of small molecules by chemical proteomics. Nat Chem Biol 5:616–24
Kidd D, Liu Y, Cravatt BF (2001) Profiling serine hydrolase activities in complex proteomes. Biochemistry 40:4005–15
Hughes TR et al. (2000) Functional discovery via a compendium of expression profiles. Cell 102:109–26
Ganter B et al. (2005) Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 119:219–44
Lamb J (2006) The connectivity map: Using Gene-Expression Signatures to Connect Small Molecules, Genes and Disease. Science 313:1929–1935
Subramanian A (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550
Josset L et al. (2010) Gene expression signature-based screening identifies new broadly effective influenza A antivirals. PLoS One doi:10.1371/journal.pone.0013169
Hassane DC et al. (2010) Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 116:5983–90
http://www.broadinstitute.org/cmap/ Accessed 15 February 2011
Barrero MJ, Izpisua Belmonte JC (2011) Regenerating the epigenome. EMBO Rep doi:10.1038/embor.2011.10
Berdasco M, Esteller M (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19:698–711
Eliseeva ED et al. (2007) Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 6:2391–8
M Yoshida (2009) Chemical genomics: a key to the epigenome – an interview with Minoru Yoshida. Int J Dev Biol 53: 269–74
Kaida D et al. (2007) Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 3:533–5
Taverna SD Cole PA (2010) Reader’s block. Nature 468:1050–1051
Fillipakopoulos P et al. (2010) Selective inhibition of BET bromodomains. Nature 468:1067–1073
Nicodeme E et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468:1119–1123
Graves PR et al. (2002) Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 62:1364–72
Wissing J et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6:537–47
Bantscheff M et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25:1035–44
Peters EC, Gray NS (2007) Chemical Proteomics Identifies Unanticipated Targets of Clinical Kinase Inhibitors. ACS Chemical Biology 2:661–664
Rix U et al. (2010) A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells INNO-406 target profile in CML. Leukemia 24:44–50
Ito T et al. (2010) Identification of a Primary Target of Thalidomide Teratogenicity. Science 327:1345–1350
Sakamoto S et al. (2009) Development and application of high-performance affinity beads: Toward chemical biology and drug discovery. The Chemical Record 9:66–85
http://www.ncgc.nih.gov/index.html Accessed 16 February 2011
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Zanders, E.D. (2012). Overview of Chemical Genomics and Proteomics. In: Zanders, E. (eds) Chemical Genomics and Proteomics. Methods in Molecular Biology, vol 800. Humana Press. https://doi.org/10.1007/978-1-61779-349-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-61779-349-3_1
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-348-6
Online ISBN: 978-1-61779-349-3
eBook Packages: Springer Protocols